다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Scientific reports, v.7, 2017년, pp.43639 -
Liao, Xin-Hua (Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou , Fujian 350122, China) , Zhang, Arina Li (Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou , Fujian 350122, China) , Zheng, Min (Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou , Fujian 350122, China) , Li, Mei-Qing (Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou , Fujian 350122, China) , Chen, Champ Peng (Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical) , Xu, Huijuan , Chu, Qing-Song , Yang, Dayun , Lu, Wenxian , Tsai, Ting-Fen , Liu, Hekun , Zhou, Xiao Zhen , Lu, Kun Ping
AI-Helper
Hepatocellular carcinoma (HCC) is one of the most prevalent and malignant cancers with high inter- and intra-tumor heterogeneity. A central common signaling mechanism in cancer is proline-directed phosphorylation, which is further regulated by the unique proline isomerase Pin1. Pin1 is prevalently o...
Mittal S. & El-Serag H. B. Epidemiology of hepatocellular carcinoma: consider the population . Journal of clinical gastroenterology 47 Suppl, S2 – 6 , doi: 10.1097/MCG.0b013e3182872f29 ( 2013 ). 23632345
Yeo W. . A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma . Journal of the National Cancer Institute 97 , 1532 – 1538 , doi: 10.1093/jnci/dji315 ( 2005 ). 16234567
Llovet J. M. . Sorafenib in advanced hepatocellular carcinoma . The New England journal of medicine 359 , 378 – 390 , doi: 10.1056/NEJMoa0708857 ( 2008 ). 18650514
Stewart B. W. & Wild C. P. World Cancer Report 2014 (IARC Nonserial Publication) ( 2014 ).
Mauro M. J. , O’Dwyer M. , Heinrich M. C. & Druker B. J. STI571: a paradigm of new agents for cancer therapeutics . Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20 , 325 – 334 ( 2002 ). 11773186
Luo J. , Solimini N. L. & Elledge S. J. Principles of cancer therapy: oncogene and non-oncogene addiction . Cell 136 , 823 – 837 ( 2009 ). 19269363
Aggarwal S. Targeted cancer therapies . Nat Rev Drug Discov 9 , 427 – 428 ( 2010 ). 20514063
Hanahan D. & Weinberg R. A. Hallmarks of cancer: the next generation . Cell 144 , 646 – 674 , doi: 10.1016/j.cell.2011.02.013 ( 2011 ). 21376230
Sjoblom T. . The consensus coding sequences of human breast and colorectal cancers . Science 314 , 268 – 274 , doi: 10.1126/science.1133427 ( 2006 ). 16959974
Liou Y. C. , Zhou X. Z. & Lu K. P. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins . Trends in biochemical sciences 36 , 501 – 514 , doi: 10.1016/j.tibs.2011.07.001 ( 2011 ). 21852138
Lu K. P. & Zhou X. Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease . Nature reviews. Molecular cell biology 8 , 904 – 916 , doi: 10.1038/nrm2261 ( 2007 ). 17878917
Zhou X. Z. & Lu K. P. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target . Nature reviews. Cancer 16 , 463 – 478 , doi: 10.1038/nrc.2016.49 ( 2016 ). 27256007
Bao L. . Prevalent overexpression of prolyl isomerase Pin1 in human cancers . Am J Pathol 164 , 1727 – 1737 , doi: 10.1016/S0002-9440(10)63731-5 ( 2004 ). 15111319
Fujimori F. , Takahashi K. , Uchida C. & Uchida T. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest . Biochemical and biophysical research communications 265 , 658 – 663 , doi: 10.1006/bbrc.1999.1736 ( 1999 ). 10600477
Wulf G. , Garg P. , Liou Y. C. , Iglehart D. & Lu K. P. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis . The EMBO journal 23 , 3397 – 3407 , doi: 10.1038/sj.emboj.7600323 ( 2004 ). 15257284
Girardini J. E. . A Pin1/mutant p53 axis promotes aggressiveness in breast cancer . Cancer Cell 20 , 79 – 91 , doi: 10.1016/j.ccr.2011.06.004 ( 2011 ). 21741598
D’Artista L. . Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc . Oncotarget , doi: 10.18632/oncotarget.7846 ( 2016 ).
Franciosa G. . Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression . Oncogene , doi: 10.1038/onc.2016.5 ( 2016 ).
Moore J. D. & Potter A. Pin1 inhibitors: Pitfalls, progress and cellular pharmacology . Bioorganic & medicinal chemistry letters 23 , 4283 – 4291 , doi: 10.1016/j.bmcl.2013.05.088 ( 2013 ). 23796453
Guo C. . Structure-based design of novel human Pin1 inhibitors (I) . Bioorganic & medicinal chemistry letters 19 , 5613 – 5616 , doi: 10.1016/j.bmcl.2009.08.034 ( 2009 ). 19729306
Hennig L. . Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone . Biochemistry 37 , 5953 – 5960 . ( 1998 ). 9558330
Wei S. . Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer . Nature medicine 21 , 457 – 466 , doi: 10.1038/nm.3839 ( 2015 ).
Fang J. . Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy . Cancer biology & therapy 1 , 614 – 620 ( 2002 ). 12642682
Huang M. E. . Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia . Blood 72 , 567 – 572 ( 1988 ). 3165295
de The H. & Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure . Nature reviews. Cancer 10 , 775 – 783 ( 2010 ). 20966922
Sanz M. A. & Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia . Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29 , 495 – 503 ( 2011 ). 21220600
Degos L. & Wang Z. Y. All trans retinoic acid in acute promyelocytic leukemia . Oncogene 20 , 7140 – 7145 , doi: 10.1038/sj.onc.1204763 ( 2001 ). 11704842
Nasr R. . Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation . Nature medicine 14 , 1333 – 1342 ( 2008 ).
Ablain J. . Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies . J Exp Med 210 , 647 – 653 ( 2013 ). 23509325
Arrieta O. . Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer . J Clin Oncol 28 , 3463 – 3471 ( 2010 ). 20547984
Budd G. T. . Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer . Clin Cancer Res 4 , 635 – 642 ( 1998 ). 9533531
Bryan M. . A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer . Investigational new drugs 29 , 1482 – 1487 , doi: 10.1007/s10637-010-9478-3 ( 2011 ). 20596747
Muindi J. . Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia . Blood 79 , 299 – 303 ( 1992 ). 1309668
Marusyk A. , Almendro V. & Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nature reviews. Cancer 12 , 323 – 334 , doi: 10.1038/nrc3261 ( 2012 ). 22513401
Lu L. C. , Hsu C. H. , Hsu C. & Cheng A. L. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges . Liver cancer 5 , 128 – 138 , doi: 10.1159/000367754 ( 2016 ). 27386431
Nault J. C. & Villanueva A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma . Clinical cancer research: an official journal of the American Association for Cancer Research 21 , 1786 – 1788 , doi: 10.1158/1078-0432.CCR-14-2602 ( 2015 ). 25628398
Shi J. Y. . Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity . Oncotarget 7 , 2867 – 2877 , doi: 10.18632/oncotarget.6558 ( 2016 ). 26672766
Pang R. . PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma . Oncogene 23 , 4182 – 4186 , doi: 10.1038/sj.onc.1207493 ( 2004 ). 15064734
Pang R. W. . PIN1 expression contributes to hepatic carcinogenesis . The Journal of pathology 210 , 19 – 25 , doi: 10.1002/path.2024 ( 2006 ). 16841372
Ao R. , Zhang D. R. , Du Y. Q. & Wang Y. Expression and significance of Pin1, beta-catenin and cyclin D1 in hepatocellular carcinoma . Molecular medicine reports 10 , 1893 – 1898 , doi: 10.3892/mmr.2014.2456 ( 2014 ). 25109821
Wang H. . PIN1 gene overexpression and beta-catenin gene mutation/expression in hepatocellular carcinoma and their significance. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 27 , 54 – 57 , doi: 10.1007/s11596-007-0116-z ( 2007 ). 17393110
Bae J. S. . PIN1 in hepatocellular carcinoma is associated with TP53 gene status . Oncology reports 36 , 2405 – 2411 , doi: 10.3892/or.2016.5001 ( 2016 ). 27499097
Huang L. . PIN1 genetic polymorphisms and the susceptibility of HBV-related hepatocellular carcinoma in a Guangxi population . Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 37 , 6599 – 6606 , doi: 10.1007/s13277-015-4539-z ( 2016 ). 26643892
Pang R. . Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis . Gastroenterology 132 , 1088 – 1103 , doi: 10.1053/j.gastro.2006.12.030 ( 2007 ). 17383430
Luo M. L. . Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer . Cancer research 74 , 3603 – 3616 , doi: 10.1158/0008-5472.CAN-13-2785 ( 2014 ). 24786790
Van Wauwe J. . Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo . The Journal of pharmacology and experimental therapeutics 261 , 773 – 779 ( 1992 ). 1374473
Liou Y. C. . Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes . Proc. Natl. Acad. Sci. USA 99 , 1335 – 1340 ( 2002 ). 11805292
Liao Y. . Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation . Oncogene 28 , 2436 – 2445 , doi: 10.1038/onc.2009.98 ( 2009 ). 19448664
Wulf G. M. . Pin1 is overexpressed in breast cancer and potentiates the transcriptional activity of phosphorylated c-Jun towards the cyclin D1 gene . EMBO J . 20 , 3459 – 3472 ( 2001 ). 11432833
Rustighi A. . The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer . Nature cell biology 11 , 133 – 142 , doi: 10.1038/ncb1822 ( 2009 ). 19151708
Ryo A. , Nakamura M. , Wulf G. , Liou Y. C. & Lu K. P. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC . Nature cell biology 3 , 793 – 801 , doi: 10.1038/ncb0901-793 ( 2001 ). 11533658
Smith M. A. . Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer . J Clin Oncol 10 , 1666 – 1673 ( 1992 ). 1403049
Lefebvre P. . Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia . Leukemia 5 , 1054 – 1058 ( 1991 ). 1774953
Villanueva A. & Llovet J. M. Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning . Nature reviews. Clinical oncology 11 , 73 – 74 , doi: 10.1038/nrclinonc.2013.243 ( 2014 ).
Ramlau R. . Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I . J Clin Oncol 26 , 1886 – 1892 , doi: 10.1200/JCO.2007.12.2614 ( 2008 ). 18398154
Decensi A. . Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women . J Clin Oncol 27 , 3749 – 3756 , doi: 10.1200/JCO.2008.19.3797 ( 2009 ). 19597031
Connolly R. M. , Nguyen N. K. & Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment . Clin Cancer Res 19 , 1651 – 1659 ( 2013 ). 23322901
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.